CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: EEF2K (ImmuneEditome ID:29904)

1. Gene summary of enriched editing regions for EEF2K

check button Gene summary
Gene informationGene symbol

EEF2K

Gene ID

29904

GeneSynonymsCaMKIII|HSU93850|eEF-2K
GeneCytomap

16p12.2

GeneTypeprotein-coding
GeneDescriptioneukaryotic elongation factor 2 kinase|alternative protein EEF2K|calcium/calmodulin-dependent eukaryotic elongation factor-2 kinase|calmodulin-dependent protein kinase III|eEF-2 kinase|elongation factor-2 kinase|eukaroytic elongation factor 2 kinase
GeneModificationdate20230329
UniprotIDO00418;H3BRH4
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr16:22216959-22217135:+ENST00000263026.8ENSG00000103319.10EEF2KintronicAluJbchr16:22216959-22217135:+.alignment
chr16:22216959-22217135:+ENST00000568269.4ENSG00000103319.10EEF2KintronicAluJbchr16:22216959-22217135:+.alignment
chr16:22231890-22232362:+ENST00000263026.8ENSG00000103319.10EEF2KintronicAluJr,AluSgchr16:22231890-22232362:+.alignment
chr16:22231890-22232362:+ENST00000568269.4ENSG00000103319.10EEF2KintronicAluJr,AluSgchr16:22231890-22232362:+.alignment
chr16:22237435-22238580:+ENST00000263026.8ENSG00000103319.10EEF2KintronicAluJr,L1ME3G,AluJb,AluSx,MIR3chr16:22237435-22238580:+.alignment
chr16:22237435-22238580:+ENST00000568269.4ENSG00000103319.10EEF2KintronicAluJr,L1ME3G,AluJb,AluSx,MIR3chr16:22237435-22238580:+.alignment
chr16:22246346-22247422:+ENST00000263026.8ENSG00000103319.10EEF2KintronicAluSz,MER21B,AluSg,MER39B,AluSx1chr16:22246346-22247422:+.alignment
chr16:22246346-22247422:+ENST00000568269.4ENSG00000103319.10EEF2KintronicAluSz,MER21B,AluSg,MER39B,AluSx1chr16:22246346-22247422:+.alignment
chr16:22274274-22275491:+ENST00000263026.8ENSG00000103319.10EEF2KintronicAluSx1,L1ME4a,AluSx3,AluJr,MIRc,L1MC4a,(TATTTT)nchr16:22274274-22275491:+.alignment
chr16:22276793-22277977:+ENST00000263026.8ENSG00000103319.10EEF2KintronicAluSq2,AluJr,AluJb,L2c,MSTDchr16:22276793-22277977:+.alignment
chr16:22285536-22286005:+ENST00000263026.8ENSG00000103319.10EEF2KUTR3AluJr,AluJochr16:22285536-22286005:+.alignment


Top

2. Tumor-specific enriched editing regions for EEF2K


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr16:22285536-22286005:+BRCAEER6.7012e-18image
ENSG00000103319.10,EEF2KBRCAEAG2.7901e-13image
chr16:22285536-22286005:+KIRCEER2.0892e-02image
ENSG00000103319.10,EEF2KKIRCEAG2.2463e-02image
chr16:22285536-22286005:+PRADEER3.2598e-02image
chr16:22285536-22286005:+THCAEER1.1854e-03image
ENSG00000103319.10,EEF2KTHCAEAG1.2281e-03image
chr16:22285536-22286005:+UCECEER1.5691e-03image
ENSG00000103319.10,EEF2KUCECEAG1.4973e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000103319.10,EEF2KKIRCPathEAG1.5924e-022.1113e-020.1039image
chr16:22285536-22286005:+KIRCPathEER3.6532e-034.7898e-030.1271image
chr16:22285536-22286005:+KIRPPathEER1.5039e-033.1908e-030.2458image
ENSG00000103319.10,EEF2KKIRPPathEAG2.4841e-032.9226e-030.2480image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr16:22285536-22286005:+ESCAEER2.2306e-022.6659e-023.0727e+03image

Top

3. Enriched editing regions and immune related genes for EEF2K


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr16:22285536-22286005:+BLCAEERENSG00000160710,ADAR0.37072.5078e-081.3412e-130.4185imageNDHX9;EIF4A3;ELAVL1;HNRNPA1;IGF2BP2;NOP56;U2AF2ADARMacrophages_M1GSVA_HALLMARK_MITOTIC_SPINDLE
chr16:22285536-22286005:+LIHCEERENSG00000158793,NIT10.41342.8733e-123.5394e-150.4089imageNEIF4A3;ELAVL1;HNRNPA1;IGF2BP2;NOP56;U2AF2NAMast_cells_restingGSVA_HALLMARK_PEROXISOME
chr16:22285536-22286005:+LIHCEERENSG00000123843,C4BPB0.38322.1129e-103.4990e-160.4223imageNEIF4A3;ELAVL1;HNRNPA1;IGF2BP2;NOP56;U2AF2C4BPBMacrophages_M0GSVA_HALLMARK_MITOTIC_SPINDLE
chr16:22285536-22286005:+LUSCEERENSG00000068079,IFI350.39812.2286e-127.3579e-180.4110imageNEIF4A3;ELAVL1;HNRNPA1;IGF2BP2;NOP56;U2AF2IFI35Macrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr16:22285536-22286005:+LUSCEERENSG00000168394,TAP10.38023.2090e-115.5609e-170.4008imageNEIF4A3;ELAVL1;HNRNPA1;IGF2BP2;NOP56;U2AF2TAP1T_cells_CD4_memory_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr16:22285536-22286005:+LUSCEERENSG00000089127,OAS10.37458.2660e-117.4079e-180.4110imageNEIF4A3;HNRNPA1;U2AF2OAS1Macrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr16:22285536-22286005:+HNSCEERENSG00000179862,CITED40.12924.7875e-021.2164e-190.4352imageNEIF4A3;IGF2BP2NANK_cells_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:22285536-22286005:+UCECEERENSG00000159377,PSMB40.46781.6067e-044.3016e-100.5114imageNDHX9;EIF4A3;ELAVL1;HNRNPA1;IGF2BP2;NOP56;U2AF2PSMB4T_cells_CD4_memory_restingGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr16:22285536-22286005:+UCECEERENSG00000187608,ISG150.45053.2523e-045.0927e-100.5096imageNDHX9;EIF4A3;ELAVL1;IGF2BP2;NOP56;U2AF2ISG15T_cells_CD4_memory_restingGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr16:22285536-22286005:+UCECEERENSG00000159352,PSMD40.43227.0393e-043.5340e-100.5136imageNDHX9;EIF4A3;ELAVL1;HNRNPA1;IGF2BP2;NOP56;U2AF2PSMD4T_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_DN

More results



Top

4. Enriched editing regions and immune related splicing for EEF2K


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr16:22285536-22286005:+
BLCAEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.37341.1453e-075.0636e-13-0.4100imageNDHX9;EIF4A3;ELAVL1;HNRNPA1;IGF2BP2;NOP56;U2AF2PRKCSHMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr16:22285536-22286005:+
HNSCEERIRENSG00000102393.5chrX101400665:101400757:101401631:1014018090.24164.7515e-042.4823e-170.4091imageNDHX9;EIF4A3;ELAVL1;HNRNPA1;IGF2BP2;NOP56;U2AF2NANK_cells_activatedGSVA_HALLMARK_HEME_METABOLISM
ENSG00000103319.10,EEF2K
HNSCEAGIRENSG00000102393.5chrX101400665:101400757:101401631:1014018090.24065.8374e-042.7435e-170.4086imageNACIN1;ADAR;AIFM1;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;METTL14;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NANK_cells_activatedGSVA_HALLMARK_HEME_METABOLISM
ENSG00000103319.10,EEF2K
STADEAGIRENSG00000198837.5chr1153930538:153931064:153932203:1539322550.42102.6539e-114.2209e-170.4430imageNACIN1;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAMacrophages_M0GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000103319.10,EEF2K
STADEAGIRENSG00000186470.9chr626373275:26373413:26374326:263743730.35975.7333e-088.9502e-150.4112imageNADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SF3A3;SF3B4;SLBP;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184BTN3A2B_cells_naiveGSVA_HALLMARK_HEME_METABOLISM
ENSG00000103319.10,EEF2K
STADEAGIRENSG00000244754.4chr1332521372:32527532:32535768:325358690.36035.8660e-087.8161e-150.4115imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NANK_cells_restingGSVA_HALLMARK_HEME_METABOLISM
ENSG00000103319.10,EEF2K
STADEAGIRENSG00000141738.9chr1739745727:39746202:39746750:397469880.35331.0112e-074.5071e-140.4028imageNAUH;BCCIP;BUD13;CSTF2T;DDX3X;DDX54;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LARP7;LIN28B;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1NANK_cells_activatedGSVA_HALLMARK_HEME_METABOLISM
ENSG00000103319.10,EEF2K
STADEAGIRENSG00000139266.5chr1257756928:57757084:57758107:577583000.39051.5510e-094.6378e-150.4158imageNADAR;AIFM1;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPD;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIAL1;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAMonocytesGSVA_HALLMARK_HEME_METABOLISM
ENSG00000103319.10,EEF2K
STADEAGIRENSG00000168137.11chr39464409:9464672:9468518:94685750.37321.7009e-092.3502e-140.4248imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL14;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAB_cells_memoryGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000103319.10,EEF2K
STADEAGIRENSG00000204138.8chr128490950:28491012:28491649:284917870.41794.8339e-113.8519e-150.4158imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NANK_cells_restingGSVA_HALLMARK_HEME_METABOLISM

More results



Top

5. Enriched editing regions and immune infiltration for EEF2K


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr16:22285536-22286005:+BLCAEERMacrophages_M11.0098e-070.3080image
ENSG00000103319.10,EEF2KBLCAEAGMacrophages_M16.1002e-070.2889image
chr16:22276793-22277977:+BRCAEERPlasma_cells2.7739e-020.4086image
chr16:22285536-22286005:+BRCAEERT_cells_CD4_memory_activated1.0169e-060.1590image
ENSG00000103319.10,EEF2KBRCAEAGDendritic_cells_activated7.1147e-060.1456image
chr16:22285536-22286005:+CESCEERT_cells_CD4_memory_resting4.5398e-04-0.2251image
ENSG00000103319.10,EEF2KCESCEAGT_cells_CD4_memory_resting4.5398e-04-0.2251image
chr16:22285536-22286005:+CHOLEERNK_cells_activated5.3097e-030.4884image
ENSG00000103319.10,EEF2KCHOLEAGNK_cells_activated4.8663e-030.4927image
ENSG00000103319.10,EEF2KCOADEAGDendritic_cells_activated2.7272e-060.3600image
chr16:22246346-22247422:+ESCAEERT_cells_CD4_memory_resting1.1435e-02-0.4973image
chr16:22285536-22286005:+ESCAEERT_cells_CD81.6268e-020.2057image
ENSG00000103319.10,EEF2KESCAEAGEosinophils3.9308e-020.1702image
chr16:22285536-22286005:+GBMEERMacrophages_M14.9636e-020.1903image
ENSG00000103319.10,EEF2KGBMEAGMacrophages_M14.9431e-020.1904image
chr16:22285536-22286005:+HNSCEERNK_cells_resting3.2349e-020.1078image
ENSG00000103319.10,EEF2KHNSCEAGNK_cells_resting3.2540e-020.1077image
chr16:22285536-22286005:+KIRCEERMacrophages_M27.6275e-05-0.2104image
ENSG00000103319.10,EEF2KKIRCEAGMacrophages_M24.6061e-04-0.1865image
chr16:22285536-22286005:+KIRPEERT_cells_gamma_delta2.5237e-040.2838image
ENSG00000103319.10,EEF2KKIRPEAGT_cells_gamma_delta2.0351e-040.2879image
chr16:22276793-22277977:+LAMLEERDendritic_cells_resting3.6209e-020.3905image
chr16:22285536-22286005:+LGGEERT_cells_CD4_memory_activated1.7208e-040.1879image
ENSG00000103319.10,EEF2KLGGEAGT_cells_CD4_memory_activated1.7293e-040.1876image
chr16:22285536-22286005:+LIHCEERMacrophages_M11.2920e-040.2058image
ENSG00000103319.10,EEF2KLIHCEAGMacrophages_M11.3331e-040.2054image
chr16:22285536-22286005:+LUADEERT_cells_CD4_memory_activated1.0858e-090.2808image
ENSG00000103319.10,EEF2KLUADEAGEosinophils3.5191e-090.2715image
chr16:22285536-22286005:+LUSCEERT_cells_CD4_memory_activated5.3371e-090.2855image
ENSG00000103319.10,EEF2KLUSCEAGT_cells_CD4_memory_activated5.3406e-090.2855image
chr16:22285536-22286005:+MESOEERT_cells_CD81.7537e-030.3674image
ENSG00000103319.10,EEF2KMESOEAGT_cells_CD81.7537e-030.3674image
chr16:22285536-22286005:+OVEERMacrophages_M13.8791e-060.2768image
ENSG00000103319.10,EEF2KOVEAGMacrophages_M18.1389e-050.2353image
chr16:22285536-22286005:+PAADEERT_cells_CD81.4944e-03-0.2514image
ENSG00000103319.10,EEF2KPAADEAGT_cells_CD81.4944e-03-0.2514image
chr16:22285536-22286005:+PCPGEERT_cells_follicular_helper5.7910e-030.2200image
ENSG00000103319.10,EEF2KPCPGEAGT_cells_follicular_helper5.7910e-030.2200image
chr16:22285536-22286005:+PRADEERT_cells_regulatory_(Tregs)3.3514e-020.1306image
ENSG00000103319.10,EEF2KREADEAGNK_cells_resting4.9243e-030.3994image
chr16:22285536-22286005:+SARCEERT_cells_CD88.4624e-050.2757image
ENSG00000103319.10,EEF2KSARCEAGT_cells_CD88.4624e-050.2757image
chr16:22285536-22286005:+SKCMEERT_cells_CD83.7821e-050.2271image
ENSG00000103319.10,EEF2KSKCMEAGT_cells_CD83.5361e-050.2280image
chr16:22216959-22217135:+STADEEREosinophils1.5212e-040.6204image
chr16:22237435-22238580:+STADEERMonocytes5.0094e-030.5646image
chr16:22274274-22275491:+STADEERPlasma_cells3.4225e-02-0.2313image
chr16:22285536-22286005:+STADEERT_cells_CD4_memory_activated3.5980e-050.2320image
ENSG00000103319.10,EEF2KSTADEAGNK_cells_activated1.1604e-020.1392image
chr16:22285536-22286005:+TGCTEERMacrophages_M23.8694e-10-0.5027image
ENSG00000103319.10,EEF2KTGCTEAGMacrophages_M23.2612e-10-0.5045image
chr16:22285536-22286005:+THCAEERDendritic_cells_activated2.6275e-030.1489image
ENSG00000103319.10,EEF2KTHCAEAGDendritic_cells_activated2.3063e-030.1509image
chr16:22285536-22286005:+THYMEERNK_cells_resting8.2856e-040.3323image
ENSG00000103319.10,EEF2KTHYMEAGNK_cells_resting8.1533e-040.3327image
chr16:22285536-22286005:+UCECEERDendritic_cells_activated1.1819e-040.3300image
ENSG00000103319.10,EEF2KUCECEAGDendritic_cells_activated3.6973e-040.3032image
chr16:22285536-22286005:+UCSEEREosinophils3.9041e-020.3276image
ENSG00000103319.10,EEF2KUCSEAGEosinophils3.9041e-020.3276image
ENSG00000103319.10,EEF2KUVMEAGNK_cells_activated3.6672e-020.3896image


Top

6. Enriched editing regions and immune gene sets for EEF2K


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
ENSG00000103319.10,EEF2KBLCAEAG4.0271e-02image9.4782e-040.1938image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr16:22285536-22286005:+CHOLEER3.5367e-02-0.37922.3321e-02-0.40631.3399e-02-0.43943.5513e-02-0.3790image
ENSG00000103319.10,EEF2KCHOLEAG3.7934e-02-0.37452.3489e-02-0.40591.2520e-02-0.44323.5694e-02-0.3786image
ENSG00000103319.10,EEF2KLUADEAG9.9159e-090.26387.2802e-100.28271.1216e-080.26292.8454e-020.1024image
chr16:22285536-22286005:+LUADEER2.3700e-110.30657.6997e-110.29881.3185e-100.29533.8606e-040.1657image
ENSG00000103319.10,EEF2KPAADEAG3.8621e-030.22931.8473e-020.18787.3291e-030.21322.8318e-040.2859image
chr16:22285536-22286005:+PAADEER3.8621e-030.22931.8473e-020.18787.3291e-030.21322.8318e-040.2859image
ENSG00000103319.10,EEF2KPCPGEAG1.5839e-03-0.25095.0938e-03-0.22322.2248e-04-0.29157.1123e-03-0.2147image
chr16:22285536-22286005:+PCPGEER1.5839e-03-0.25095.0938e-03-0.22322.2248e-04-0.29157.1123e-03-0.2147image
ENSG00000103319.10,EEF2KSTADEAG7.1420e-03-0.14831.0150e-03-0.18063.9990e-03-0.15851.3379e-03-0.1764image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000103319.10,EEF2KBLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.9518e-090.3443image
chr16:22285536-22286005:+BLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.1319e-110.3750image
chr16:22276793-22277977:+BRCAGSVA_HALLMARK_DNA_REPAIREER3.1321e-020.4005image
chr16:22285536-22286005:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.5290e-350.3898image
ENSG00000103319.10,EEF2KBRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.3852e-170.2729image
chr16:22285536-22286005:+CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.9134e-070.3291image
ENSG00000103319.10,EEF2KCESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.9134e-070.3291image
chr16:22285536-22286005:+CHOLGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.3281e-02-0.4399image
ENSG00000103319.10,EEF2KCHOLGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.3157e-02-0.4404image
ENSG00000103319.10,EEF2KCOADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG5.2434e-06-0.3503image
chr16:22285536-22286005:+ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.2014e-030.2510image
chr16:22246346-22247422:+ESCAGSVA_HALLMARK_UV_RESPONSE_UPEER1.0338e-020.5032image
chr16:22285536-22286005:+GBMGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER1.0933e-02-0.2451image
ENSG00000103319.10,EEF2KGBMGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG1.1337e-02-0.2440image
chr16:22285536-22286005:+HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.1871e-040.1927image
ENSG00000103319.10,EEF2KHNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.2535e-040.1920image
ENSG00000103319.10,EEF2KKIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.3146e-040.1874image
chr16:22285536-22286005:+KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.1967e-050.2254image
ENSG00000103319.10,EEF2KKIRPGSVA_HALLMARK_PROTEIN_SECRETIONEAG9.2948e-04-0.2577image
chr16:22285536-22286005:+KIRPGSVA_HALLMARK_PROTEIN_SECRETIONEER9.8527e-04-0.2565image
chr16:22276793-22277977:+LAMLGSVA_HALLMARK_ANDROGEN_RESPONSEEER4.0321e-02-0.3830image
ENSG00000103319.10,EEF2KLAMLGSVA_HALLMARK_ANDROGEN_RESPONSEEAG2.6333e-04-0.3904image
chr16:22285536-22286005:+LGGGSVA_HALLMARK_MYOGENESISEER2.0460e-060.2363image
ENSG00000103319.10,EEF2KLGGGSVA_HALLMARK_MYOGENESISEAG2.0620e-060.2359image
chr16:22285536-22286005:+LIHCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.5429e-070.2748image
ENSG00000103319.10,EEF2KLIHCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.7478e-070.2740image
ENSG00000103319.10,EEF2KLUADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG8.4290e-10-0.2817image
chr16:22285536-22286005:+LUADGSVA_HALLMARK_E2F_TARGETSEER8.6424e-130.3269image
chr16:22285536-22286005:+LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.7647e-110.3237image
ENSG00000103319.10,EEF2KLUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.7182e-110.3238image
ENSG00000103319.10,EEF2KMESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG3.5566e-040.4149image
chr16:22285536-22286005:+MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER3.5566e-040.4149image
chr16:22246346-22247422:+OVGSVA_HALLMARK_COAGULATIONEER2.9750e-020.3076image
chr16:22285536-22286005:+OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.7698e-170.4825image
ENSG00000103319.10,EEF2KOVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.2557e-090.3429image
ENSG00000103319.10,EEF2KPAADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.3892e-04-0.2995image
chr16:22285536-22286005:+PAADGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.3892e-04-0.2995image
chr16:22285536-22286005:+PCPGGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER7.9003e-05-0.3107image
ENSG00000103319.10,EEF2KPCPGGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG7.9003e-05-0.3107image
ENSG00000103319.10,EEF2KPRADGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG4.9142e-05-0.2449image
chr16:22285536-22286005:+PRADGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER9.8906e-05-0.2369image
ENSG00000103319.10,EEF2KREADGSVA_HALLMARK_HEME_METABOLISMEAG7.6841e-03-0.3802image
ENSG00000103319.10,EEF2KSARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.3824e-060.3280image
chr16:22285536-22286005:+SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.3824e-060.3280image
ENSG00000103319.10,EEF2KSKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.5790e-070.2819image
chr16:22285536-22286005:+SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.6489e-070.2816image
ENSG00000103319.10,EEF2KSTADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.5112e-13-0.3895image
chr16:22274274-22275491:+STADGSVA_HALLMARK_ANGIOGENESISEER4.8498e-020.2160image
chr16:22246346-22247422:+STADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER1.4095e-030.4480image
chr16:22285536-22286005:+STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.0298e-060.2555image
chr16:22285536-22286005:+TGCTGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER3.3071e-11-0.5281image
ENSG00000103319.10,EEF2KTGCTGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.5328e-11-0.5308image
chr16:22285536-22286005:+THCAGSVA_HALLMARK_KRAS_SIGNALING_DNEER9.5769e-050.1924image
ENSG00000103319.10,EEF2KTHCAGSVA_HALLMARK_KRAS_SIGNALING_DNEAG9.7151e-050.1922image
ENSG00000103319.10,EEF2KTHYMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.5287e-040.3733image
chr16:22285536-22286005:+THYMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.4878e-040.3740image
chr16:22285536-22286005:+UCECGSVA_HALLMARK_UV_RESPONSE_DNEER3.4194e-04-0.3082image
ENSG00000103319.10,EEF2KUCECGSVA_HALLMARK_UV_RESPONSE_DNEAG2.8837e-04-0.3084image
ENSG00000103319.10,EEF2KUCSGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.2905e-030.4535image
chr16:22285536-22286005:+UCSGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.2905e-030.4535image


Top

7. Enriched editing regions and drugs for EEF2K


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000103319.10,EEF2KBLCACGP.60474EAG3.0464e-10-0.3601image
chr16:22285536-22286005:+BLCACGP.60474EER8.3184e-12-0.3890image
chr16:22285536-22286005:+BRCACGP.082996EER5.9361e-08-0.1760image
ENSG00000103319.10,EEF2KBRCAJNK.Inhibitor.VIIIEAG3.1230e-07-0.1656image
chr16:22276793-22277977:+BRCAImatinibEER4.7550e-030.5095image
ENSG00000103319.10,EEF2KCESCAZD6244EAG1.6328e-05-0.2748image
chr16:22285536-22286005:+CESCAZD6244EER1.6328e-05-0.2748image
ENSG00000103319.10,EEF2KCHOLMetforminEAG1.1328e-02-0.4488image
chr16:22285536-22286005:+CHOLMetforminEER1.1763e-02-0.4467image
ENSG00000103319.10,EEF2KCOADGW843682XEAG1.3876e-090.4546image
ENSG00000103319.10,EEF2KDLBCEmbelinEAG1.1342e-020.5076image
chr16:22246346-22247422:+ESCAAMG.706EER4.3537e-03-0.5609image
chr16:22285536-22286005:+ESCAJNK.Inhibitor.VIIIEER1.3148e-02-0.2122image
ENSG00000103319.10,EEF2KGBMFTI.277EAG2.0390e-020.2240image
chr16:22285536-22286005:+GBMFTI.277EER1.9969e-020.2247image
ENSG00000103319.10,EEF2KHNSCBMS.509744EAG1.5012e-05-0.2162image
chr16:22285536-22286005:+HNSCBMS.509744EER1.5017e-05-0.2162image
ENSG00000103319.10,EEF2KKIRCAZD.2281EAG9.8654e-10-0.3201image
chr16:22285536-22286005:+KIRCCisplatinEER2.0126e-07-0.2743image
chr16:22285536-22286005:+KIRPKIN001.135EER9.8293e-050.3012image
ENSG00000103319.10,EEF2KKIRPAZD6482EAG3.1625e-050.3208image
ENSG00000103319.10,EEF2KLAMLJNK.Inhibitor.VIIIEAG1.1620e-030.3505image
chr16:22285536-22286005:+LGGAP.24534EER5.1443e-070.2494image
ENSG00000103319.10,EEF2KLGGAP.24534EAG5.1671e-070.2491image
ENSG00000103319.10,EEF2KLIHCAUY922EAG2.5158e-080.2960image
chr16:22285536-22286005:+LIHCAUY922EER2.5211e-080.2960image
ENSG00000103319.10,EEF2KLUADGemcitabineEAG4.8222e-12-0.3155image
chr16:22285536-22286005:+LUADGemcitabineEER8.2601e-12-0.3132image
chr16:22285536-22286005:+LUSCGemcitabineEER2.6104e-05-0.2078image
ENSG00000103319.10,EEF2KLUSCGemcitabineEAG2.6082e-05-0.2078image
chr16:22285536-22286005:+MESOA.770041EER3.6714e-03-0.3428image
ENSG00000103319.10,EEF2KMESOA.770041EAG3.6714e-03-0.3428image
ENSG00000103319.10,EEF2KOVBexaroteneEAG4.1985e-080.3232image
chr16:22285536-22286005:+OVBexaroteneEER7.0086e-090.3432image
ENSG00000103319.10,EEF2KPAADAZD6482EAG4.9811e-040.2791image
chr16:22285536-22286005:+PAADAZD6482EER4.9811e-040.2791image
ENSG00000103319.10,EEF2KPCPGMidostaurinEAG3.4150e-040.2831image
chr16:22285536-22286005:+PCPGMidostaurinEER3.4150e-040.2831image
ENSG00000103319.10,EEF2KPRADDocetaxelEAG9.8477e-040.2002image
chr16:22285536-22286005:+PRADEmbelinEER1.3785e-030.1955image
chr16:22285536-22286005:+READBIRB.0796EER8.0316e-030.3821image
ENSG00000103319.10,EEF2KREADA.770041EAG8.7058e-08-0.6888image
chr16:22285536-22286005:+SARCCisplatinEER7.1598e-05-0.2784image
ENSG00000103319.10,EEF2KSARCCisplatinEAG7.1598e-05-0.2784image
ENSG00000103319.10,EEF2KSKCMAG.014699EAG1.2548e-030.1790image
chr16:22285536-22286005:+SKCMAG.014699EER1.2624e-030.1789image
chr16:22237435-22238580:+STADCyclopamineEER3.4037e-02-0.4435image
ENSG00000103319.10,EEF2KSTADBMS.708163EAG2.5450e-04-0.2007image
chr16:22274274-22275491:+STADAZD.0530EER5.5147e-03-0.3057image
chr16:22246346-22247422:+STADIPA.3EER2.0336e-020.3340image
chr16:22216959-22217135:+STADBortezomibEER7.2344e-030.4657image
chr16:22285536-22286005:+STADCI.1040EER6.2556e-04-0.1929image
chr16:22285536-22286005:+TGCTFTI.277EER3.0779e-060.3865image
ENSG00000103319.10,EEF2KTGCTFTI.277EAG2.7229e-060.3885image
ENSG00000103319.10,EEF2KTHCADasatinibEAG1.3422e-05-0.2145image
chr16:22285536-22286005:+THCADasatinibEER1.2576e-05-0.2151image
ENSG00000103319.10,EEF2KTHYMMidostaurinEAG6.8602e-030.2714image
chr16:22285536-22286005:+THYMMidostaurinEER6.8460e-030.2715image
chr16:22285536-22286005:+UCECA.443654EER4.4651e-05-0.3487image
ENSG00000103319.10,EEF2KUCECGDC.0449EAG9.8946e-05-0.3299image
ENSG00000103319.10,EEF2KUCSEmbelinEAG1.5275e-020.3810image
chr16:22285536-22286005:+UCSEmbelinEER1.5275e-020.3810image
ENSG00000103319.10,EEF2KUVMCGP.082996EAG2.3278e-020.4201image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType